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Abstract 
Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare 
disease, which mainly affects women in their fifth to seventh decades of life. It is a 
chronic autoimmune disease characterized by a progressive damage of 
interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids 
retention. Even if the disease usually presents a long asymptomatic phase and a 
slow progression, in many patients it may progress faster toward cirrhosis and its 
complications. The 10 year mortality is greater than in diseases such as human 
immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. 
Ursodeoxycholic acid is the only treatment available today, but even if effective in 
counteracting the disease progression for the majority of patients, in approximately 
40% is not able to decrease effectively the alkaline phosphatase, a surrogate 
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marker of disease activity. Recently, obeticholic acid received the European 
Medicines Agency conditional approval, as add on treatment in patients non 
responders or intolerant to ursodeoxycholic acid. The present paper illustrates the 
opinion of a working group, composed by clinical pharmacologists, 
gastroenterologists/hepatologists with specific expertise on Primary Biliary 
Cholangitis and patient associations, on the state of the art and future 
perspectives of the disease management. The agreement on the document was 
reached through an Expert Meeting. 
Keywords: ursodeoxycholic acid, alkaline phosphatase; obeticholic acid, fibrates, 
budesonide.  
Introduction 
As its prevalence is below 5 cases out of 10,000, Primary Biliary Cholangitis (PBC) 
is a rare disease according to the European Union criteria. Its former 
denomination, Primary Biliary Cirrhosis, was changed into Primary Biliary 
Cholangitis, leaving the PBC abbreviation unaffected, in the year 2015. The 
change of nomenclature was made to address the demands from patient 
organizations and providers in the sector so as to remove the term cirrhosis, which 
only refers to the end stage of the disease. Indeed, as of today, PBC is generally 
diagnosed in the earlier phases of the disease and treatments are often capable of 
blocking progression. For this reason, labeling PBC patients as cirrhotic was 
frustrating and incoherent as well [1].  
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PBC is a chronic autoimmune disease electively affecting interlobular bile ducts 
(cholangitis) leading to retention of bile salts into the liver (cholestasis) and 
secondary damage of hepatocytes. The onset is often silent and insidious but the 
disease may progress toward cirrhosis, liver failure and death.  
As PBC is a rare disease, the issues related to it concern, among others, 
diagnosis, care and shared management of the patient not only by specialized 
centers but also in the local outpatient healthcare setting.  
To study this rare condition there has been an international effort to build up a 
network on centres studying PBC. The Global PBC Group, an international 
independent working group, was established in 2012 with the aim of setting up a 
collaboration among centers involved in the scientific research program on PBC. 
All data collected from patients followed by these centers are merged into a single 
database which accounts for more than 6,000 patients as of today [2].  
The present document is the outcome of the consensus reached within an Italian 
working group of experts on the disease (physicians, pharmacologists and 
patients) and its purpose is to establish shared recommendations with regard to 
disease management and treatment for the benefit of the providers of the sector.   
Epidemiology: according to the latest estimates, patients affected by PBC 
range from 12 to 13,000 in Italy. 
Global PBC prevalence and incidence provided in the latest Orphanet report are 
2.1/10,000 and 0.3/10,000/year, respectively [3]. Two revisions of the 
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epidemiological studies conducted in various geographical regions, North America 
(US and Canada), Northern Europe (Norway, Finland, Sweden, Denmark and UK), 
Spain, Israel and Australia, were published in 2012 and 2013 [4, 5], showing a 
marked variability of epidemiological data among the different regions, with 
prevalence ranging from 0.09 to 4.02/10,000 and incidence ranging from 0.03 to 
0.58/10,000/year. As discussed by the authors, such variability is likely due to the 
varying degree of access to diagnosis and care rather than an actual geographic 
difference in the epidemiology of the disease.  
No specific PBC register is currently in place in Italy. According to the only 
available Italian epidemiological study conducted by Lleo et al. in 2016 [6] and 
based on administrative databases in Region Lombardy in the 2000-2009 
timeframe, the number of prevalent PBC cases is 2,970 in a population of 
9,742,676 inhabitants as of January 1st 2010. The authors estimated a nationwide 
prevalence of 2.95 PBC cases every 10,000 inhabitants and an incidence of 
0.167/10,000/year. As reported in the paper, epidemiological data refer to a 
population aged over 20 years old. However, the ICD9 (International Classification 
of the Diseases) code 571.6 used to identify cases of PBC in administrative 
databases is not specific for PBC as it includes all types of biliary cirrhosis, 
although the majority of them is certainly represented by PBC. After adjusting data 
for age (according to ISTAT 2016 data 82% of the Italian population is aged over 
20 years old) the total number of PBC cases in Italy equals 14,675, while applying 
a 10% correction factor due to non PBC-specificity of the ICD9 code 571.6 the 
estimated number of PBC cases in Italy drops to 13,207. 
6 
 
 
Data reported by Lleo et al. (2016) [6] are consistent with what has been reported 
by Orphanet (12,740 prevalent cases applying the 2.1/10,000 global prevalence to 
the Italian population). Therefore, we can assume that the number of PBC 
prevalent cases in Italy ranges from 12,740 [3] to 13.207 [6]. 
Prognostic factors: men, women below 45 years old and patients in 
advanced stage of disease at the time of the diagnosis have a higher risk of 
non-response to ursodeoxycholic acid (UDCA). An absent or partial 
response to UDCA is the strongest predictor of poor outcome. 
PBC typically affects women aged from 50 to 60 years old [7-9]. The silent form of 
PBC is characterized by positivity of anti-mitochondrial antibodies (AMA), while 
liver biochemistry is normal. The silent form is often found in close relatives or 
patients who underwent an AMA test requested by another specialist. From 70% 
to 80% of these patients will develop symptoms of the disease over 20 to 30 years 
[10, 11]. The asymptomatic form of PBC is characterized by AMA positivity and 
increase of serum alkaline phosphatase (ALP), although no symptoms are 
present. Less than 5% of these patients remain asymptomatic over 20 years [12]. 
Fatigue and pruritus typically appear in the symptom phase. The symptomatic 
onset has mainly been noticed in young women affected by most biochemically 
active forms of disease, less responsive to treatment with UDCA and in whom 
disease progression was faster [13].   
UDCA is the recommended first-line agent for treatment of PBC, where the 
optimum dose is 13–15 mg/kg per day [7]. Biochemical response to UDCA in PBC 
is highly variable among patients. Response rates are lower in male patients and 
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in young women (<45 years old) [14]. An absent or partial response to UDCA is 
the strongest predictor of poor outcome [14]. 
From the histological point of view, the disease progression occurs through four 
stages as originally defined by Ludwig (stage 1 defined by portal inflammation; 
stage 2 corresponding to the extension of this inflammation beyond portal tracts 
into the surrounding parenchyma, with or without associated duct loss; stage 3 
where fibrous septa link adjacent portal triads and, stage 4 representing cirrhosis). 
A meta-analysis by Ishibashi et al. 2011 [15, 16] showed that 50% of PBC patients 
with moderate fibrosis localized in the portal area develop cirrhosis within 4 years, 
compared to 31% of patients where fibrosis is absent. Furthermore, out of 667 
PBC patients, 5.9% who were at cirrhotic or pre-cirrhotic stage developed 
hepatocellular carcinoma (HCC) over 20 years. No PBC patient with moderate or 
no fibrosis developed HCC over the same timeframe [15, 17].   
In addition to UDCA response and histology, the following markers at the time of 
diagnosis identify patients with a worse prognosis: histological ductopenia, 
PBC/autoimmune hepatitis overlap syndrome, greater than normal bilirubin levels, 
low levels of albumin [18, 19].  
From a genetic perspective, the DRB1*0801 allele of the Human Leucocyte 
Antigen (HLA) showed an association with PBC in four distinct cohorts: the 
Canadian/US cohort (2009), the Italian/Canadian/US cohort (2010), the UK cohort 
(2011), and the Japanese cohort (2012). However, these are single-center studies 
and the results should be validated over wider geographical regions [20]. 
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With regard to serum prognostic markers, an association was described [21, 22] 
between anti-gp210 positivity and the progression of the disease towards liver 
failure. Furthermore, in patients presenting anti-centromere antibodies, PBC more 
often progresses towards portal hypertension. This finding is certainly remarkable, 
but validation studies in European populations are needed before being able to 
consider it as a patient stratification criterion. 
Diagnosis of PBC: diagnosis of PBC is based on the evidence of persistent 
increase of serum ALP in association with AMA positivity. 
Currently, most of the patients are diagnosed in the asymptomatic phase of the 
disease and symptoms generally appear from 2 to 4 years after diagnosis.   
The EASL [7] and AASLD [23] guidelines agree on the following PBC diagnostic 
criteria: 
1. Persistent increase (>6 months) of serum levels of alkaline phosphatase (ALP) in 
patients with normal results at ultrasound examination of the biliary tract; 
2. Positivity of AMA (title >1:40 at IF measurement) or anti-Sp100 and anti gp210 
subtypes of anti nuclear antibodies (ANA); 
3. Histologic evidence of nonsuppurative obstructive cholangitis involving interlobular 
bile ducts. 
At least two of the criteria listed above must be met for the diagnosis of PBC. 
Presence of AMA is fundamental, while in case of absence a histologic 
examination is needed to confirm diagnosis. There is general agreement that AMA 
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positivity and ALP increase allow definitive diagnosis as the positive predictive 
value exceeds 95% in this case. Thus, in most of the cases liver biopsy is not 
required for diagnosis. Biopsy is necessary for diagnostic purposes in the following 
conditions:  
1. Patients with persistent increase of ALP of hepatic origin while negative to AMA, 
M2 antibodies or for PBC-specific ANA subtypes (anti Sp100 and anti gp210). 
2. Patients with PBC with a clinical and laboratory picture suggesting the presence of 
features of autoimmune hepatitis (serum transaminases >5 times the upper normal 
limit, IgG >2 times the upper normal limit, ANA+ (>1:320), SMA positivity (>1:80)) 
or in whom other liver diseases must be excluded. 
Another potential indication for liver biopsy that could help the patient 
management is the lack of response to UDCA. The histologic examination is the 
reference tool for the assessment of the stage of PBC and fibrosis, but this test is 
invasive, has non-negligible risks, is not easily accepted by patients and cannot be 
used for the periodic assessment of disease progression. Alternative non-invasive 
methods to assess the stage of fibrosis, including unidimensional transient 
elastography (Fibroscan), which evaluates the elasticity of liver parenchyma (the 
so called liver stiffness), are being evaluated. Recent studies show that liver 
stiffness values <9.6 kPa identify patients with poor or no disease progression 
over a six year follow up period. Reversely, about 30% of patients with liver 
stiffness values >9.6 kPa incur major disease-related events over a six year 
period. During repeated follow up liver stiffness measurements, an increase equal 
or superior to 2.1 kPa enables to select patients with the highest risk of incurring 
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liver disease-related major events, liver failure, liver transplantation, and death 
[24]. It must be highlighted, however, that there are currently no data proving the 
predictive ability of liver stiffness with regard to drug treatment efficacy.  
Also the APRI index (AST to Platelet Ratio Index) has been proposed as an 
independent predictor of advanced fibrosis and worse transplant free 
survival with cutpoint = 0.54 [25].  
Identification of surrogate markers able to reliably predict the clinical outcome of 
patients is demanding [26]. Currently, only the serum levels of ALP, both at the 
time of diagnosis and during treatment with UDCA, are acknowledged as markers 
of progression. Indeed, there is wide evidence in medical literature that abnormal 
serum levels of ALP (especially when two times upper normal limit), are predictive 
of progressive disease [27, 28]. 
Managing PBC: managing PBC patients means managing symptoms, 
outcomes of cholestasis and chronic liver disease.    
The approach to a patient affected by PBC is not substantially different from 
managing a patient affected by another liver disease, although with features 
related to the management of symptoms and the assessment of disease 
progression. Obviously, also PBC patients need to be monitored with regard to 
comorbidities and risk factors (alcohol intake, obesity, viruses, etc.). Liver 
biochemistry should be checked on a yearly basis in the early stages of the 
disease, and then every 3 to 6 months in more advanced stages. Above all, 
attention must be drawn at the potential onset of PBC/autoimmune hepatitis 
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overlap through monitoring of transaminases and possibly IgG (in case of 
hypertransaminasemia), as patient's prognosis and treatment course would 
markedly change in this case. As it was already said, the assessment of liver 
stiffness at the time of diagnosis via Fibroscan might be useful to identify the 
progressive forms of the disease, but how to schedule follow up Fibroscan is 
currently uncertain.  
Managing symptoms: pruritus should be treated with cholestyramine (first 
line), rifampicin (second line) or naltrexone (third line); UDCA and 
antihistamine drugs are inefficacious. No treatment for fatigue has been 
reported to be of significant benefit so far [7].   
Severe pruritus has an impact on the quality of life of PBC patients, suffice it to say 
that severe drug resistant pruritus is an indication to liver transplant. Given its 
remarkable impact on patients' quality of life, this symptom requires particular 
clinical attention. Neither UDCA nor anti histamine drugs showed efficacy in the 
treatment of pruritus. The first line drug is cholestyramine, an ion exchange resin 
able to bind bile acids in the intestinal lumen. The recommended dosage of 
cholestyramine in treating pruritus is 4g per day up to 4 times daily (from 4 to 16 g 
per day). Rifampicin (from 150 to 600 mg per day) is considered as a second line 
drug, but it requires close monitoring because of potential liver toxicity occurring in 
10% of patients. The third line drug is naltrexone (50 mg per day), which is 
recommended to be started at low dose and then increased, with the risk of 
suspension syndrome requiring medical attention. The use of sertraline, a 
serotonin reuptake inhibitor, in a crossover study conducted versus placebo (from 
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50 to 100 mg per day) in patients with cholestasis of various etiology, has been 
reported to have positive effects on pruritus. This drug is effective in approximately 
40% of patients [7, 29]. 
Fatigue is a poorly specific and generally multifactorial symptom. First of all, 
common and treatable causes of fatigue (anemia, hypothyroidism, depression, 
psychotropic drug abuse, etc.) should be excluded in these patients. Fatigue due 
to PBC is not correlated with the severity or duration of the disease. In some cases 
it is disabling and prevents the most common daily activities. Eighty percent of 
patients with PBC present fatigue, often associated with sleep disorders and 
orthostatic hypotension. No specific drug treatment for fatigue or dedicated 
guidelines are available as of today; furthermore, drugs that are widespread in the 
age group who is most affected by PBC, like blood pressure lowering drugs, may 
exacerbate the condition of fatigue. Results of a recent randomized double-blind 
study with modanafil for the treatment of PBC patients for 12 weeks compared to 
placebo showed ineffectiveness of this drug for the management of fatigue in 
patients with PBC [30]. The results of a clinical trial on the efficacy of rituximab for 
this indication are not yet available [31].  
Managing the outcomes of chronic cholestasis: supplementation with 
calcium and vitamin D should be considered in perimenopausal women as 
treatment of osteoporosis. The administration of alendronate or ibandronate 
might be considered in osteopenic patients in non cirrhotic stage. 
Hyperlipidemia needs to be treated only in patients with family history of 
significant cardiovascular events [7].  
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Due to malabsorption of vitamin D, osteoporosis is often associated with PBC (in 
20 to 52% of patients) and progresses along with cholestasis. However, it is 
important to remind that patients with PBC are mainly women in post-menopausal 
age, who are per se at risk of developing osteoporosis. Consensus is missing 
between European and American guidelines with regard to treatment of 
osteoporosis. Supplementation with calcium (1000 to 1500 mg per day) and 
Vitamin D (1000 IU per day) should be considered in these patients and in post-
menopausal women in particular. Such treatments are routine in the management 
of osteoporosis and do not depend on the diagnosis of PBC. The administration of 
alendronate (70 mg weekly) or ibandronate (150 mg monthly) might be considered 
in osteopenic patients in non cirrhotic stage. Data demonstrating the efficacy of 
ibandronate once a month in preventing fractures have been reported [32], but 
further studies are needed to confirm these results. 
Hyperlipidemia is a common outcome of chronic cholestasis. However, the 
absence of an additional cardiovascular risk in these patients has been 
demonstrated [33]. In patients with family history of significant cardiovascular 
events, or hypercholesterolemia associated with low levels of HDL, lipid lowering 
drugs should be considered. 
Managing cirrhosis. Managing cirrhosis secondary to PBC is not 
substantially different from managing cirrhosis of other etiology. 
Managing cirrhosis due to PBC is not substantially different from managing 
cirrhosis of other etiology. The incidence of HCC in PBC patients is estimated at 
0.36 per 100 person years where male sex, an advanced histologic stage and 
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inadequate response to UDCA being associated with higher risk [34]. In order to 
monitor the onset of HCC, an ultrasound surveillance every 6 months is required 
[7]. 
In presence of ultrasound signs of portal hypertension, platelet levels <140,000 or 
Mayo Risk score >4.1, an endoscopic examination should be performed in order to 
assess the presence of esophageal varices. [35]. Management of esophageal 
varices involves the use of non-selective beta-blockers or elastic banding as 
primary and secondary prevention. Good clinical outcomes of transplantation have 
been reported, with 80 to 85% survival rate over 5 years and almost universal 
recurrence of the disease [36]. Patients with PBC should be referred to a 
transplant center in presence of MELD score >12, Mayo Risk Score ≥ 7.8 or when 
bilirubin levels get close to 6 mg/dl, given that bilirubin levels are a much more 
accurate prognostic indicator in PBC than in liver diseases of other etiology. 
Although the progression of PBC is slow, it is potentially serious: suffice it to 
mention that the 10 year mortality rate is 59% in PBC patients with greater than 
normal bilirubin levels and 38% in patients with ALP >2 ULN [37]; markedly higher 
with respect to diseases like HCV/HIV coinfection (25%) [38] or mammary 
carcinoma (29%) [39]. For this reason, it is essential to identify the right treatment 
capable of blocking the progression of the disease in UDCA non responders or 
intolerants.   
Treating PBC: UDCA is the only drug approved as first line treatment of the 
disease. Consensus is missing with regard to second line or alternative to 
UDCA treatments for patients who are non responders or intolerant to this 
drug. 
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As of today, UDCA is the only drug approved as first line treatment of PBC and the 
only one recommended by the international guidelines [7, 23]. The drug was 
proven to be effective in reducing serum biochemical parameters altered in PBC 
(ALP, bilirubin, GGT, cholesterol, and IgM) and also in slowing the progression of 
the disease. The main mechanisms of action of UDCA are linked with its choleretic 
effect and with its effect on the secretion of bicarbonates protecting the biliary 
epithelium from the detergent activity of hydrophobic biliary salts. A clinical trial 
demonstrated that the likelihood of transplant or death in PBC patients is reduced 
by a 4 year treatment with UDCA compared to placebo as early as in 1994 [40]. 
Following studies demonstrated slower disease progression along with reduced 
rate of major liver events and need of transplant in patients treated with UDCA 
compared to control patients [16]. Thus, UDCA is certainly a valid treatment option 
for patients with PBC; however, in a part of the patient population (around 40%) 
the drug is ineffective in reducing biochemical markers, ALP in particular. 
Furthermore, from 3 to 5% of patients are intolerant to UDCA, manifesting adverse 
events that prevent continuing the drug, for example incoercible or otherwise 
unexplained diarrhea. 
The definition of UDCA non-responder is not completely clear, as different criteria 
have been reported in medical literature [41]. These criteria (Table 1) are based on 
the improvement of biochemical markers of the disease (ALP, gamma-GT, 
albumin, bilirubin) after 6 to 12 months of treatment. All studies agree that the 
response to UDCA, whatever the definition, represents an independent prognostic 
factor of disease progression.  
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Therefore, the percentage of patients who are non-responders to UDCA changes 
according to the chosen marker; by and large, 40% of patients treated with UDCA 
need an add-on treatment, while 3 to 5% of patients are intolerant to the drug, that 
is, they manifest adverse events that de facto prevent them from taking it. All 
models that have been proposed to define the lack of response to UDCA (table 1) 
are easy to use but also dichotomous, namely they are able to define only two 
levels of risk (responder and non-responder). Conversely, these models are not 
able to provide intermediate levels of risk and, above all, they do not measure risk 
over time, in other words they do not predict the likelihood that a patient will 
undergo transplant after 1 to 5 years. In order to drive decisions on patient 
management, it is necessary to provide continuous models (indices, scores) with 
the power to measure the level of risk for each single patient in each disease 
stage and, above all, to quantify risk over time. Two large multicenter studies have 
recently developed continuous predictive models (UK score, Globe score) that are 
based on biochemical markers related to stage of disease and response to UDCA, 
and therefore allow to quantify and stratify the risk of progression in continuous 
and time related fashion [42, 43]. Using such models is it possible to quantify the 
risk of developing liver failure requiring transplant or liver and non liver related 
mortality over a specific timeframe (5,10 and 15 years) in single patients. 
Treating PBC patients non responding to UDCA: although randomized 
clinical trials are lacking, some studies support potential efficacy of 
budesonide and fibrates 
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With regard to add on therapies to UDCA, according to published studies 
budesonide and fibrates (bezafibrate, fenofibrate) are of benefit in patients who do 
not respond to UDCA. However, these are single center or retrospective studies 
conducted in very small patient populations and requiring validation [44, 45]. 
Budesonide might be of more benefit in PBC patients with signs of hepatitis 
(elevated serum transaminases) in whom the inflammatory component is 
prevailing, but it cannot be used in patients at cirrhotic stage, with severe 
osteopenia/osteoporosis, elderly, or who suffer from diabetes or hypertension. 
Fibrates might be useful in patients with marked hyperlipidemia and high 
cardiovascular risk, and in patients with pruritus as a prevailing symptom, but they 
carry potential side effects like muscle damage (myositis and rhabdomyolysis) and 
renal insufficiency; fibrates may also cause drug induced liver damage. 
As of today, OCA is the only drug for which controlled multicenter studies have 
demonstrated efficacy in the UDCA non-responder or intolerant patient sub group 
[46].  
Obeticholic acid (OCA) might be considered as add on therapy in UDCA non-
responders or intolerants.   
OCA belongs to the class of bile acids, being an analogue of chenodeoxycholic 
acid (CDCA), with the addition of an ethyl group providing a strong affinity for the 
nuclear farnesoid X receptor (FXR). This receptor is involved in the regulation of 
bile acids homeostasis, inhibiting their production (via the inhibition of CYP7A1 
and CYP8A1) [47], increasing their excretion [48] and reducing liver and intestinal 
reabsorption [49, 50]. OCA has a 100 times higher affinity for FXR than CDCA, 
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and a different mechanism of action from UDCA, whose primary activity is the 
dilution of the endogenous bile [51]. 
Based on the results of two phase II studies and one phase III study (POISE), 
OCA received a conditional approval by EMA [52]. In the phase II 747 202 study, 
OCA in combination with UDCA was proven to reduce ALP by 20-25% in a non 
dose-dependent fashion after a 12 week treatment. In these studies the reduction 
of ALP is clinically and statistically significant as early as after two weeks of 
treatment, reaches a peak after 6 months and then stabilizes [53]. 
The POISE study evaluated a composite primary endpoint recommended by FDA 
and based on the following elements: ALP<1.67 + ALP reduction of at least by 
15% from baseline and total bilirubin (TB) lower than or equal to the Upper Limit of 
Normal (ULN) at 12 months. The secondary endpoints evaluated were the 
reductions of biochemical markers: ALP, AST, bilirubin and GGT. The study 
included three treatment arms: OCA 10mg ± UDCA, Titration (OCA 5mg ± UDCA 
for 6 months with the OCA dose increased to 10mg for the following 6 months) 
and placebo ± UDCA. Patients were randomized in 1:1:1 ratio. The primary 
endpoint was reached by 46 to 47% of patients taking OCA, with an earlier effect 
in the OCA 10mg treatment arm. OCA was proven effective in reducing ALP, AST 
and GGT, achieving clinically and statistically significant levels after two weeks of 
treatment. ALP, AST and GGT reached their lowest levels after three months and 
then remained stable for the whole study period, as it was seen in phase II studies. 
Furthermore, a reduction of ALP by at least 15% was reported in 77% of patients. 
Two hundred and sixteen patients, of whom 32 from Italy, were enrolled in the 
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study. The improvement in the markers of cholestasis was also confirmed by the 
following 12-month open-label phase [46]. 
The main adverse event was pruritus, that was the reason for study interruption for 
7 out of 73 patients in the OCA 10 mg treatment arm and 1 out of 70 in the titration 
arm. However, pruritus suffered by patients decreased over time and reached the 
same level as at baseline after six months [46].  
Conclusions 
UDCA shows to be effective in a wide range of patients, although 30 to 40% of 
them are still lacking an adequate response. Globe Score and UK PBC Risk Score 
seem a very promising support to the decisions that must be made concerning 
follow-up and indications for second-line drugs. As of today, in theory, at least 
three drugs can be used as an add-on to UDCA in an individualized fashion 
according to the characteristics of the patient affected by PBC. Of them, only OCA 
received conditional approval by EMA. With regard to the other two options, 
budesonide and fibrates, the current off label utilization still requires further 
scientific evidence, especially in terms of validation through randomized clinical 
trials.   
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Table 1.  Qualitative or quantitative indices assessing the 
prognosis of PBC on the basis of biochemical response to 
ursodeoxycholic acid 
 
 
 
Indices 
UDCA-response 
criteria 
Time of 
evaluation 
after starting 
UDCA 
Predictive Performance* 
Global 
PBC 
Study 
Group 
UK PBC 
Consortium 
Qualitative 
Toronto 
 
ALP ≤ 1.67 x ULN 
 
2 y 
 
0.61 
 
0.70 
Barcelona ALP normal or ALP 
reduction > 40% 
1 y 0.58 0.61 
Paris-I ALP < 3 x ULN, AST< 2 x 
ULN, normal bilirubin 
1 y 0.70 0.81 
Rotterdam Normal bilirubin, 
normal albumin 
1 y 0.69 - 
Paris-II ALP < 1.5 x ULN, AST < 
1.5 x ULN, normal 
1y 0.63 0.75 
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bilirubin 
Global-PBC ALP < 2 x ULN, normal 
bilirubin 
1 y - - 
Rochester ALP < 2 x ULN, Mayo 
Score <4.5 
6 m - - 
Ehime Normal GGT or GGT 
reduction > 70% 
6 m - - 
Quantitative 
UK score 
 
ALP, AST/ALT and 
bilirubin at y + albumin 
and platelet count at 
baseline 
 
1y 
 
- 
 
0.95 
Globe Score ALP, bilirubin, albumin 
and platelet count at y 
+ age at baseline 
1y 0.81 - 
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Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GGT, gammaglutamyl transpeptidase; IgG, 
immunoglobulin G; LSM, liver stiffness measurement; UDC, ursodeoxycholic acid; ULN, times the 
upper limit of normal.  
*= predictive performance based on C-statistic for all-cause death or LT, derived from the 
derivation and validation of cohorts of the Global PBC study group [43] or the UK PBC 
Consortium [42]. Adapted from Corpechot C. et al. 2016 [41] 
